US-based life sciences giant Thermo Fisher Scientific Inc., (NYSE: TMO) has announced an expansion of its strategic partnership with China-based contract research organization (CRO) Sangon Biotech. This development builds upon their initial agreement signed in August 2023, which now encompasses gas chromatography-mass spectrometry (GC/MS) in addition to the gene science field.
Enhancing Quality Control and Industrial Production
The partnership will capitalize on Thermo Fisher’s expertise in GC/MS and Sangon’s strengths in industrial operations and localization. This collaboration aims to enhance the quality control and solutions for in vitro diagnosis and biopharmaceutical applications. The expansion is anticipated to markedly improve the quality control capabilities and production throughput for Sangon, particularly in the manufacturing of upstream pharmaceutical diagnostic core raw materials, including Oligo synthesis. Financial details of the agreement were not disclosed.- Flcube.com